Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Merck Sharp & Dohme LLC
Beijing Biotech
Parabilis Medicines, Inc.
VA Office of Research and Development
Pfizer
NRG Oncology
IDEAYA Biosciences
Aulos Bioscience, Inc.
Arsenal Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Eli Lilly and Company
K36 Therapeutics, Inc.
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Orano Med LLC
Eli Lilly and Company
Eli Lilly and Company
GI Innovation, Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Mayo Clinic
UroTrials Company (GmbH)
Xijing Hospital
Alterome Therapeutics, Inc.
ViroMissile, Inc.
Rutgers, The State University of New Jersey
Northwestern University
Tizona Therapeutics, Inc
Tasca Therapeutics
Essen Biotech
Essen Biotech
Clasp Therapeutics, Inc.
Angiex, Inc.
Ottawa Hospital Research Institute
MacroGenics
Astellas Pharma Inc
University of Oklahoma
Institut Bergonié
Kidney Cancer Research Bureau
HiberCell, Inc.
Memorial Sloan Kettering Cancer Center
Palo Alto Veterans Institute for Research
OncoNano Medicine, Inc.
MOMA Therapeutics
Sairopa B.V.
Regeneron Pharmaceuticals